Stock ATTBF ABATTIS BIOCEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Abattis Bioceuticals Corp.

Equities

ATTBF

CA00258G1037

Market Closed - OTC Markets
Other stock markets
 11:18:09 16/05/2024 pm IST 		5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for Abattis Bioceuticals Corp. -99.00% 0.00%
2020 Abattis Bioceuticals Corp. Reports Earnings Results for the Full Year Ended September 30, 2019 CI
2019 Abattis Bioceuticals Corp. Announces Board Changes CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Abattis Bioceuticals Corp. Reports Earnings Results for the Full Year Ended September 30, 2019
CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) cancelled the acquisition of NutriVida Corp.
CI
Abattis Bioceuticals Corp. Reports Earnings Results for the Third Quarter Ended June 30, 2019
CI
Abattis Bioceuticals Corp.'s Equity Buyback announced on August 7, 2018, has expired.
CI
Abattis Bioceuticals Corp. Reports Earnings Results for the Full Year Ended September 30, 2018
CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) cancelled the acquisition of Winston Resources Inc..
CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) completed the acquisition of Pro Natura BV from The Catalyst Capital Group Inc.
CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) agreed to acquire Pro Natura BV from The Catalyst Capital Group Inc. for €15.7 million.
CI
Abattis Bioceuticals Corp Announces Launch of Its New Website and Provide an Operational Update
CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) signed a letter of intent to acquire NutriVida Corp. for CAD 15 million.
CI
Abattis Bioceuticals Corp Signs a Distribution Agreement with Shefield &Sons Tobacconists Inc. to Sell the Abattis Vaporizer Line in all Shefield &Sons Stores Across Canada
CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) acquired Select Strains Inc. for $3.5 million.
CI
Abattis Intends To Seek Acquisitions
CI
Abattis Bioceuticals Corp. Provides Update on Vaporizer Product Line
CI
Abattis Bioceuticals Provides Phase 1 Update on Research and Development for Nanoemulsification and Liposomal Platforms of Cannabinoid-Rich Hemp Oil
CI
Abattis Bioceuticals Corp. Announces the Pending Release of “Comfort”, A Nutraceutical Designed to Target Chronic Pain and Inflammation
CI
Abattis Bioceuticals Corp. to Launch New Products Through Vergence Naturals
CI
Emerald Health Therapeutics, Inc. completed the acquisition of 35% stake in Northern Vine Canada Inc. from Abattis Bioceuticals Corp. (OTCPK:ATTB.F).
CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) announces an Equity Buyback for 20,986,909 shares, representing 5% of its issued share capital.
CI
Abattis Bioceuticals Corp's Board intends to launch an Equity Buyback.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATTBF Stock
  4. News Abattis Bioceuticals Corp.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW